Schedule 13G ownership disclosure

ORIC Pharmaceuticals Inc

Common Stock, $0.0001 par value per share · CUSIP: 68622P109

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • VIKING GLOBAL INVESTORS LP

    Shares: 8,729,345 · Class: 9.99%

  • Viking Global Opportunities Parent GP LLC

    Shares: 8,729,345 · Class: 9.99%

  • Viking Global Opportunities GP LLC

    Shares: 5,606,787 · Class: 6.42%

  • Viking Global Opportunities Portfolio GP LLC

    Shares: 5,606,787 · Class: 6.42%

  • Viking Global Opportunities Illiquid Investments Sub-Master LP

    Shares: 5,606,787 · Class: 6.42%

  • Viking Global Opportunities Drawdown GP LLC

    Shares: 3,122,558 · Class: 3.57%

  • Viking Global Opportunities Drawdown Portfolio GP LLC

    Shares: 3,122,558 · Class: 3.57%

  • Viking Global Opportunities Drawdown (Aggregator) LP

    Shares: 3,122,558 · Class: 3.57%

  • HALVORSEN OLE ANDREAS

    Shares: 8,729,345 · Class: 9.99%

  • Ott David C.

    Shares: 8,729,345 · Class: 9.99%

  • Shabet Rose Sharon

    Shares: 8,729,345 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-25-002996
Form type
SCHEDULE 13G/A
Filer
Oric Pharmaceuticals, Inc.
CIK
CIK 1796280
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub